Learn how to bridge the gap between clinical studies and patient support programs to enhance the depth and quality of your real-world data and give patients easier access to new life-changing treatments.
Clinical studies are vital in the development and commercialization of new drugs and treatment options. However, for rare disease patients, the opportunity to participate in clinical trials can be infrequent and challenging. And for pharma firms, conducting observational studies can be an enormous undertaking.
But what if there was a solution to this challenge, one that would make post-marketing and Phase IV studies with rare disease patients more manageable for both patients and drug manufacturers?
In this guide, we explore the potential integration of clinical studies with patient support programs (PSP) to make them more accessible for patients and improve the depth and quality of their output for pharma firms.
Detailing the advantages and challenges of this holistic approach, the article covers:
Offered Free by: Sciensus
See All Resources from: Sciensus